A simple blood test that measures lymphocyte count may accurately predict response to chimeric antigen receptor T-cell therapy among patients with relapsed multiple myeloma, according to study results.
Nearly all patients with multiple myeloma eventually relapse. CAR T-cell therapy that targets B-cell maturation antigen (BCMA) — a protein expressed at high levels on the surface of multiple myeloma cells — is one potential treatment option for patients whose disease progressed on other therapies.
Mark Bustoros, MD, assistant professor of medicine at Weill Cornell Medicine, and
